March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Comparing Intravenous Pilocarpine and Carbachol Iontophoresis Stimulated Accommodation in Rhesus Monkeys
Author Affiliations & Notes
  • Mark Wendt
    College of Optometry, University of Houston, Houston, Texas
  • Lin He
    College of Optometry, University of Houston, Houston, Texas
  • Adrian Glasser
    College of Optometry, University of Houston, Houston, Texas
  • Footnotes
    Commercial Relationships  Mark Wendt, None; Lin He, None; Adrian Glasser, None
  • Footnotes
    Support  NEI grant R01EY14225 and NEI Core Grant P30 EY007551
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 1357. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mark Wendt, Lin He, Adrian Glasser; Comparing Intravenous Pilocarpine and Carbachol Iontophoresis Stimulated Accommodation in Rhesus Monkeys. Invest. Ophthalmol. Vis. Sci. 2012;53(14):1357.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Many studies have used carbachol iontophoresis (CARB-ionto) or topical pilocarpine eye drops to pharmacologically stimulate accommodation in Rhesus monkeys. These methods hinder ocular measurements at the time of drug application, provide inconsistent results, and have a slow time-course. Here, the utility, safety, time-course, stability and repeatability of intravenous pilocarpine (iv-PILO) and CARB-ionto stimulated accommodation are compared.

Methods: : Experiments were performed under anaesthesia on 5 previously iridectomized monkeys aged 10 to 16 years. In 3 monkeys, accommodation was stimulated with CARB-ionto in 5 successive experiments and refraction measured with a Hartinger coincidence refractometer. In separate experiments, accommodation was stimulated using a 5 mg/kg bolus of iv-PILO given over 30 seconds followed by a continuous infusion of 20 mg/kg/hr for 5.5 minutes in 3 successive experiments with the same monkeys as well as in single experiments with 2 additional monkeys. Accommodation was reversed with 0.15 mg/kg i.v. glycopyrrolate. Refraction was measured continuously with photorefraction with initial and final refraction measurements also made with the Hartinger. In subsequent iv-PILO experiments with each monkey, accommodative changes in lens equatorial diameter were measured continuously with video-image analysis.

Results: : Maximum accommodation of 3 monkeys was mean ± SD: 14.0 ± 3.4; range: 9.9 - 20.7 D with CARB-ionto (5 repeats) and 11.0 ± 1.4; 8.8 - 13.0 D with iv-PILO stimulation (3 repeats). The average of the standard deviations of maximum accommodation from each monkey was 1.8 ± 1.8 D from 5 CARB-ionto experiments and 0.6 ± 0.40 from 3 iv-PILO experiments. The average latency to the start of the response after CARB-ionto administration was 9.6 ± 6.5; 0.8 - 20.8 minutes with a time constant of 15.6 ± 13.5; 2.6 - 47.3 minutes. The average latency after iv-PILO administration was 18.8 ± 1.4; 15.2 - 20.6 seconds with a time constant of 11.6 ± 4.4; 6.8 - 18.9 seconds, followed by a stable refractive nadir. There were no adverse side-effects of any kind. During iv-PILO stimulated accommodation in 5 monkeys, lens diameters decreased by 0.54 ± 0.09; 0.42 - 0.62 mm with a rate of change of 0.05 ± 0.01; 0.04 - 0.06 mm/D.

Conclusions: : Intravenous administration of pilocarpine produces a 90 times faster accommodative response than carbachol iontophoresis with more consistent and stable accommodative changes as indicated by smaller standard deviations from multiple experiments. Relatively rapidly occurring, safe, repeatable ocular accommodative responses can be measured continuously, unhindered, using intravenous pilocarpine stimulation in anesthetized rhesus monkeys.

Keywords: accommodation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×